Systemic corticosteroid use to manage uncontrolled asthma and its associated healthcare
burden may account for important health-related adverse effects. We conducted a systematic …

Although oral corticosteroids are effective, due to side-effects corticosteroid-sparing
strategies must be used and one should aim at short-term use with the lowest effective dose …

Monoclonal antibody therapies have significantly improved treatment outcomes for patients
with severe asthma; however, a significant disease burden remains. Available biologic …

The discovery of IgE represented a major breakthrough in allergy and asthma research,
whereas the clinical interest given to IgE in asthma has been blurred until the arrival of anti …

Background Assessment of clinical outcomes in the real-world corroborates findings from
randomized controlled trials (RCTs). Objective This meta-analysis evaluated real-world data …

Omalizumab was the first, and for a long time the only available monoclonal antibody for the
add-on treatment of severe allergic asthma. In particular, omalizumab selectively targets …

Antibodies are well established in mainstream clinical practice and present an exciting area
for collaborative research and development in industry and academia alike. In this review …

Abstract We reviewed 24 'real‐life'effectiveness studies of omalizumab in the treatment of
severe allergic asthma that included 4117 unique patients from 32 countries with significant …

BACKGROUND: Since initial registration, the omalizumab clinical trial database has
expanded considerably, with a doubling of patients exposed in the clinical trial environment …

Background After the approval of omalizumab for severe allergic asthma, a total of 25
studies have evaluated the effectiveness of omalizumab under “real-life” conditions of …